In addition, refractory/relapsed MM (RRMM) patients have shown limited therapeutic benefits from programmed death 1 (PD‐1)/programmed death ligand 1 (PD‐L1) antibodies, despite their high efficacy in treating some solid tumors.[4] To improve their efficacy, a clinical trial that combined the checkpoint inhibitors with the Food and Drug Association (FDA)‐approved first‐line immune modulator drug lenalidomide was conducted. This evidence concerns the gene CD274 and Miyoshi myopathy.